Drugs / MK-3577
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00868790 | Mar 2009 → Jul 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | Met primary Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3577 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00868790 ↗ |
| Action | Inhibit | “Glucagon receptor antagonist” CHEMBL1933350 ↗ |
| Modality | Small molecule | — CHEMBL1933350 ↗ |
| Route | Oral | “MK-3577 oral tablets” NCT00868790 ↗ |
| Target | GCGR | “Glucagon receptor antagonist” CHEMBL1933350 ↗ |